Kardigan, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 11, 2026, covering the fiscal quarter ended June 30, 2026.

Key Highlights

  • Share count: As of August 7, 2026, Kardigan had 93,503,699 shares of common stock, par value $0.00001 per share, outstanding.
  • Company classification: Kardigan is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Clinical programs: The company disclosed ongoing trials including the Phase 2b Cohort 1 trial of Danicamtiv (KINSHIP-DCM), the Phase 2b trial of KATALYST-AV, and the KARDINAL-ASH Phase 2 clinical trial.
  • Key product candidates: According to the filing, the company's business is highly dependent on Danicamtiv for genetic DCM, Ataciguat for moderate CAVS, and Tonlamarsen for post-hospitalization management of ASH.
  • Financial condition: The company disclosed that it "has incurred significant financial losses since our inception and anticipates that we will continue to incur significant financial losses for the foreseeable future."
  • Capital needs: The filing states the company "will require substantial additional capital in order to finance our operations."

Kardigan's Clinical-Stage Operations and Capital Position in Q2 2026

Kardigan, Inc. (NASDAQ:KARD), a clinical-stage biopharmaceutical company incorporated in Delaware and headquartered in Princeton, NJ, filed its Form 10-Q for the quarterly period ended June 30, 2026. The filing reported 93,503,699 shares of common stock outstanding as of August 7, 2026. The company noted it had not filed all reports required during the preceding 12 months, checking "No" for that compliance question on the cover page.

According to the filing, Kardigan's business centers on three primary product candidates: Danicamtiv, targeting genetic dilated cardiomyopathy (DCM); Ataciguat, targeting moderate calcific aortic valve stenosis (CAVS); and Tonlamarsen, targeting post-hospitalization management of acute severe hypertension (ASH). The company disclosed that topline data is anticipated from the ongoing Phase 2b Cohort 1 trial of Danicamtiv KINSHIP-DCM, the Phase 2b KATALYST-AV trial, and the KARDINAL-ASH Phase 2 trial, though no specific timing was confirmed in the extracted filing text.

The filing described Kardigan as having "a limited operating history" and warned that the "successful development of pharmaceutical products involves a lengthy and expensive process and is highly uncertain." The company also disclosed that if it is "unable to raise such capital when needed, or on acceptable terms," it "could be forced to delay, reduce or eliminate" its product development programs. The filing also references the company's Prolaio platform as a development focus. All forward-looking statements in the filing are the company's own and are subject to the cautionary language included in the quarterly report.

What Was Disclosed

Kardigan filed its Form 10-Q for the quarter ended June 30, 2026, reporting 93,503,699 shares outstanding, ongoing clinical trials across three product candidates, continued operating losses, and a stated need for additional capital to fund operations.